152 related articles for article (PubMed ID: 33829073)
1. Postoperative or Salvage Proton Radiotherapy for Prostate Cancer After Radical Prostatectomy.
Kharod SM; Mercado CE; Morris CG; Bryant CM; Mendenhall NP; Mendenhall WM; Nichols RC; Hoppe BS; Liang X; Su Z; Li Z; Henderson RH
Int J Part Ther; 2021; 7(4):52-64. PubMed ID: 33829073
[TBL] [Abstract][Full Text] [Related]
2. Initial report of the genitourinary and gastrointestinal toxicity of post-prostatectomy proton therapy for prostate cancer patients undergoing adjuvant or salvage radiotherapy.
Deville C; Jain A; Hwang WT; Woodhouse KD; Both S; Wang S; Gabriel PE; Christodouleas JP; Bekelman J; Tochner Z; Vapiwala N
Acta Oncol; 2018 Nov; 57(11):1506-1514. PubMed ID: 30028227
[TBL] [Abstract][Full Text] [Related]
3. Five- and seven-year outcomes for image-guided moderately accelerated hypofractionated proton therapy for prostate cancer.
Henderson RH; Bryant CM; Nichols RC; Mendenhall WM; Hoppe BS; Su Z; Morris CG; Mendenhall NP
Acta Oncol; 2022 Apr; 61(4):468-477. PubMed ID: 34965846
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 trial of guideline-based postoperative image guided intensity modulated radiation therapy for prostate cancer: Toxicity, biochemical, and patient-reported health-related quality-of-life outcomes.
Berlin A; Cho E; Kong V; Howell KJ; Lao B; Craig T; Bayley A; Chung P; Gospodarowicz M; Warde P; Catton C; Bristow RG; Ménard C
Pract Radiat Oncol; 2015; 5(5):e473-e482. PubMed ID: 25899220
[TBL] [Abstract][Full Text] [Related]
5. Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer.
Bryant C; Smith TL; Henderson RH; Hoppe BS; Mendenhall WM; Nichols RC; Morris CG; Williams CR; Su Z; Li Z; Lee D; Mendenhall NP
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):422-434. PubMed ID: 27084658
[TBL] [Abstract][Full Text] [Related]
6. Patient-reported Outcomes and Late Toxicity After Postprostatectomy Intensity-modulated Radiation Therapy.
Akthar AS; Liao C; Eggener SE; Liauw SL
Eur Urol; 2019 Nov; 76(5):686-692. PubMed ID: 31113644
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial.
Sargos P; Chabaud S; Latorzeff I; Magné N; Benyoucef A; Supiot S; Pasquier D; Abdiche MS; Gilliot O; Graff-Cailleaud P; Silva M; Bergerot P; Baumann P; Belkacemi Y; Azria D; Brihoum M; Soulié M; Richaud P
Lancet Oncol; 2020 Oct; 21(10):1341-1352. PubMed ID: 33002438
[TBL] [Abstract][Full Text] [Related]
8. Risk adapted dose-intensified postoperative radiation therapy in prostate cancer patients using a simultaneous integrated boost technique applied with helical Tomotherapy.
Beck M; Wust P; Barelkowski T; Kaul D; Thieme AH; Wecker S; Wlodarczyk W; Budach V; Ghadjar P
Radiat Oncol; 2017 Aug; 12(1):125. PubMed ID: 28793907
[TBL] [Abstract][Full Text] [Related]
9. Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer.
Lewis SL; Patel P; Song H; Freedland SJ; Bynum S; Oh D; Palta M; Yoo D; Oleson J; Salama JK
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):605-11. PubMed ID: 26867889
[TBL] [Abstract][Full Text] [Related]
10. Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): A Mono-institutional Report on Feasibility and Acute Toxicity.
Fersino S; Tebano U; Mazzola R; Giaj-Levra N; Ricchetti F; Di Paola G; Fiorentino A; Sicignano G; Naccarato S; Ruggieri R; Cavalleri S; Alongi F
Clin Genitourin Cancer; 2017 Aug; 15(4):e667-e673. PubMed ID: 28237181
[TBL] [Abstract][Full Text] [Related]
11. Preliminary Analysis of a Phase II Trial of Stereotactic Body Radiation Therapy for Prostate Cancer With High-Risk Features After Radical Prostatectomy.
Laughlin BS; Voss MM; Toesca DAS; Daniels T; Golafshar MA; Keole SR; Wong WW; Rwigema JC; Davis B; Schild SE; Stish BJ; Choo R; Lester S; DeWees TA; Vargas CE
Adv Radiat Oncol; 2023; 8(2):101143. PubMed ID: 36845611
[TBL] [Abstract][Full Text] [Related]
12. Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial.
Leite ETT; Ramos CCA; Ribeiro VAB; Salvajoli BP; Nahas WC; Salvajoli JV; Ynoe Moraes F
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1263-1270. PubMed ID: 33346091
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial.
Kneebone A; Fraser-Browne C; Duchesne GM; Fisher R; Frydenberg M; Herschtal A; Williams SG; Brown C; Delprado W; Haworth A; Joseph DJ; Martin JM; Matthews JHL; Millar JL; Sidhom M; Spry N; Tang CI; Turner S; Wiltshire KL; Woo HH; Davis ID; Lim TS; Pearse M
Lancet Oncol; 2020 Oct; 21(10):1331-1340. PubMed ID: 33002437
[TBL] [Abstract][Full Text] [Related]
14. Comparative toxicity outcomes of proton-beam therapy versus intensity-modulated radiotherapy for prostate cancer in the postoperative setting.
Santos PMG; Barsky AR; Hwang WT; Deville C; Wang X; Both S; Bekelman JE; Christodouleas JP; Vapiwala N
Cancer; 2019 Dec; 125(23):4278-4293. PubMed ID: 31503338
[TBL] [Abstract][Full Text] [Related]
15. 5-Year Outcomes of a Prospective Phase 1/2 Study of Accelerated Hypofractionated Radiation Therapy to the Prostate Bed.
Martell K; Cheung P; Morton G; Chung H; Deabreu A; Zhang L; Pang G; Alayed Y; Mamedov A; Gladwish A; Loblaw A
Pract Radiat Oncol; 2019; 9(5):354-361. PubMed ID: 31103715
[TBL] [Abstract][Full Text] [Related]
16. Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer.
Gorovets D; Hopkins M; Kollmeier M; Moore A; Goel A; Shasha D; Brennan V; McBride S; Cohen G; Damato AL; Zelefsky MJ
Brachytherapy; 2021; 20(6):1099-1106. PubMed ID: 34588146
[TBL] [Abstract][Full Text] [Related]
17. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy.
Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
Eur Urol; 2011 Dec; 60(6):1142-8. PubMed ID: 21855208
[TBL] [Abstract][Full Text] [Related]
18. Four-Year Outcomes From a Prospective Phase II Clinical Trial of Moderately Hypofractionated Proton Therapy for Localized Prostate Cancer.
Grewal AS; Schonewolf C; Min EJ; Chao HH; Both S; Lam S; Mazzoni S; Bekelman J; Christodouleas J; Vapiwala N
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):713-722. PubMed ID: 31199994
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy.
Feng M; Hanlon AL; Pisansky TM; Kuban D; Catton CN; Michalski JM; Zelefsky MJ; Kupelian PA; Pollack A; Kestin LL; Valicenti RK; DeWeese TL; Sandler HM
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1417-23. PubMed ID: 17418972
[TBL] [Abstract][Full Text] [Related]
20. Moderate hypofractionated post-prostatectomy radiation therapy is feasible and well tolerated: experience from a single tertiary cancer centre.
Valero J; Montero A; Hernando O; Izquierdo M; Sánchez E; García-Aranda M; López M; Ciérvide R; Martí J; Álvarez B; Alonso R; Chen-Zhao X; Fernández-Letón P; Rubio C
Clin Transl Oncol; 2021 Jul; 23(7):1452-1462. PubMed ID: 33433839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]